



## **Symic to Present at the 27<sup>th</sup> Annual Piper Jaffray Healthcare Conference**

**SAN FRANCISCO, Dec. 1, 2015** – Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 27th Annual Piper Jaffray Healthcare Conference in New York.

Conference details are as follows:

Date: Tuesday, Dec. 1, 2015

Time: 3:50 p.m. EST

Location: The New York Palace Hotel

### **About Symic**

Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic's proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. SB-030 is Symic's lead compound under evaluation in the Phase 1/2 SHIELD clinical trial for vascular endothelial injury.

Symic is based in San Francisco. For additional information, please visit the company's website at <http://www.symic.bio> or follow us on Twitter at [www.twitter.com/symicbio](http://www.twitter.com/symicbio) and LinkedIn at [www.linkedin.com/company/symic-bio/](http://www.linkedin.com/company/symic-bio/).

###

### **Media Contacts**

David Schull or Lena Evans

Russo Partners, LLC

(212) 845-4271

(212) 845-4262

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[lana.evans@russopartnersllc.com](mailto:lana.evans@russopartnersllc.com)